In contrast, IDH-wildtype gliomas usually present as glioblastomas (GBM), the most common and clinically aggressive World Health Organization (WHO) grade IV gliomas, with a median survival of 15–18 months despite aggressive multimodality therapy [8, 9]. Here, IDH2 is linked to central nervous system cancer.